Our new website represents the beginning of a new internet business strategy that we believe will enable us to communicate with the many communities we deal with, said Jack Gemmell, Nymox’s general counsel and chief information officer in a press statement. We expect that our new internet presence will allow us more easily and cost-effectively to offer and sell our products such as our AlzheimAlert(TM) test. It will enable us to provide more complete information to the medical community, patients and caregivers, investors and shareholders as well as the public at large about our products and their medical indications and about our ongoing research programs into such important areas as therapeutics for Alzheimer’s disease and treatments for E. coli contamination.
